HIV / AIDS

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.

The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.

In the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.

Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.

Our panel discusses this patient group and the challenges associated with their care.

In this episode, clinicians discuss challenges associated with these topics and offer management insights on them.

In this case study, clinicians review a challenging case.

In our latest roundtable series, we cover different aspects of HIV care. In this series, clinicians discuss diagnosis, therapies such as long-acting injectables, treating patients with multidrug resistance and more.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.

An expert on HIV discusses recent real-world studies and research on patient-reported outcomes, detailing treatment algorithms under investigation and their reported tolerability.

Sorana Segal-Maurer, MD, reviews research evaluating the efficacy of B/F/TAF compared with other HIV treatment regimens, including dolutegravir plus tenofovir/FTC.

An infectious disease specialist discusses the differences in binding affinity between dolutegravir and bictegravir and how it informs treatment selection.

Sorana Segal-Maurer, MD, provides an overview of treatment guidelines for the management of patients with HIV and provides insights on currently available therapeutic regimens.

Addressing patients with HIV who have fallen out of care, Shauna Applin, ARNP, provides clinical insights on treatment options and best practices for restarting therapy.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.

An expert on HIV provides clinical insights on the rationale for switching therapies and ways to educate patients on treatment decisions.

Shauna Applin, ARNP, provides comprehensive insights on factors that inform treatment decisions for patients with HIV.

The panel concludes its discussion by talking about resources available for providers in managing their patients with HIV who experience drug resistance.

Experts on HIV offer insights into switching therapies for patients with a history of resistance, highlighting ways to simplify and optimize treatment.

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.